Two weeks ago (19 Mar), a federal jury in San Francisco found Monsanto’s Roundup weed killer was a substantial factor in causing cancer in a Californian man, Edwin Hardeman. Mr Hardeman was the first person to challenge Monsanto’s Roundup in a federal court. During the trial, the 70-year-old testified that he had use the weed killer for a long period of time and at one time got it on his skin before he was diagnosed with cancer.

The ruling at the federal court followed a historic verdict last August in which a California state court ruled that Roundup caused the terminal cancer of Dewayne Johnson, a former school groundskeeper. In Mr Johnson’s case, the jury found Monsanto had “acted with malice or oppression” and awarded him US$289 million in damages. The damages were later reduced to US$78 million.

After the federal court found Monsanto’s weed killer was responsible for Mr Hardeman’s cancer, the jury deliberated on the damages to be awarded to Mr Hardeman last Wed (27 Mar) and decided on the amount of US$80 million. The jury found the German pharmaceutical giant Bayer liable because its subsidiary, Monsanto, did not warn the plaintiff of the herbicide’s alleged cancer risks.

Not surprisingly, Bayer share price dropped. It has been steadily sinking since the first adverse verdict in the Roundup lawsuit was announced last August. The drop in share price has pushed Bayer’s value down to about US$58 billion since then. It is now trading at below 60 EUR.

In fact, it was Singapore’s Temasek Holdings which helped Bayer to acquire Monsanto. It was reported in Apr last year that Bayer sold 3.6 per cent stake to Temasek for 3 billion euros at 96.77 euros per share. The money is used as part of Bayer’s plan to takeover Monsanto. Together with its existing holding in Bayer, Temasek would then own about 4 percent in Bayer after the transaction. By Jun, with Temasek’s help, Bayer successfully acquired Monsanto to become the biggest seed and agricultural chemical maker in the world.

As of Friday’s (29 Mar) closing, Bayer’s share price was 57.60 euros. Since Temasek bought 3 billion euros worth of shares at 96.77 euros in Apr last year, that means it has lost 39.17 euros per share or 40.5% of the 3 billion euros investment. So, in less than a year, Temasek has lost at least 1.2 billion euros or S$1.85 billion.

Bayer continues to deny that Roundup could cause cancer, “This (second) verdict does not change the weight of over four decades of extensive science and the conclusions of regulators worldwide that support the safety of our glyphosate-based herbicides and that they are not carcinogenic.”

Third trial against Monsanto started

The Hardeman trial is only the second of more than 11,200 Roundup lawsuits set to go to trial in the US.

A third Roundup lawsuit started in California’s Superior Court in Oakland last Thu (28 Mar). It was brought by California elderly couple Alva and Alberta Pilliod who were diagnosed with non-Hodgkin’s lymphoma in 2011 and 2015 respectively.

Alva was diagnosed with systemic non-Hodgkin lymphoma in 2011 and has been in remission since, after undergoing aggressive chemotherapy treatment that degraded his cognitive function. Alberta was diagnosed with the same cancer in 2015 after doctors found a tumor in the middle of her brain. She was declared cancer-free in 2016 following a round of chemotherapy that left her with extensive brain damage, but relapsed the next year. A second round of treatment stabilized the tumor.

The probability that both Alva and Alberta would get non-Hodgkin lymphoma is 1 in 20,000, the plaintiffs’ lawyer told the jury. Their treating physician said it was so unlikely they would both develop the same cancer that an environmental factor like Roundup was the likely culprit.

The plaintiffs’ lawyer also revealed new evidence in court, alleging that Monsanto planted one of its employees at a contract lab called Industrial Bio-Test Laboratories (IBT) in the 1970s to fake negative mouse carcinogenicity data for Roundup’s active ingredient glyphosate. The alleged fake data would then be used to win regulatory approval for the weed killer in 1975. The lawyer also alleged that Monsanto had planned an attack to discredit the World Health Organization’s (WHO) cancer research agency, anticipating that it would classify glyphosate as a probable human carcinogen in 2015.

Furthermore, the lawyer intended to show that Monsanto had exploited “deep connections” within the US Environmental Protection Agency (EPA) to classify glyphosate as non-carcinogenic. In fact, a toxicologist in the University of California at Berkeley, was “so outraged” by the EPA’s failure to follow its own herbicide-assessment guidelines that she recently resigned from an EPA glyphosate-review panel to conduct her own study of the chemical. That study, released this past February, found that glyphosate exposure increases the risk of developing non-Hodgkin lymphoma.

The lawyer told the jury in the third trial that Monsanto has known for 40 years that Roundup causes tumors in rodents and for 20 years that it causes non-Hodgkin lymphoma in humans, but refused to include a cancer warning to safeguard the enormous profits generated by the most widely used herbicide in the world.

“You give the consumer the right to make a choice” about a chemical that “causes cancer before they buy it,” he said. “Because that failure means people get hurt, and they have to deal with the consequences. That’s how it works.”

The latest new evidence against Monsanto in the third trial was not presented in the previous two trials, where both juries found Monsanto liable nonetheless.

Meanwhile, Monsanto’s lawyer argued that the elderly couple already have several known risk factors for non-Hodgkin lymphoma. Alva has a history of skin cancer – he has been diagnosed with multiple forms of it 22 times – the autoimmune disorder ulcerative colitis, and five bouts of meningitis. The lawyer said that auto-immune conditions like ulcerative colitis increase the risk of developing non-Hodgkin lymphoma. And meningitis is “an extremely rare condition” that weakened Alva’s immune system, he said.

Monsanto’s lawyer also pointed out that Alberta had bladder cancer before, which more than doubles the risk of non-Hodgkin lymphoma and Hashimoto’s disease, a condition in which the immune system attacks the thyroid gland. With this condition, the risk of non-Hodgkin lymphoma is tripled, he said.

He rounded out his remarks by noting that 100 countries have deemed Roundup safe to sell since the herbicide was developed in 1974. He added that regulators in the US, Canada and Europe re-reviewed glyphosate after the WHO’s cancer agency announced its findings and again concluded that glyphosate is safe.

“When you see the EPA’s determination,” the Monsanto’s lawyer said, “it is backed by solid science.”

Other than California, Monsanto’s Roundup weed killer trials are also expected to start in other States soon. For example, at least two trials are scheduled to take place in St. Louis, Missouri state court in the second half of this year.

Even as more cases are waiting to be heard in US courts, more cancer sufferers are also queuing up to file suits against Monsanto. Do expect Bayer’s share price to tank further if Monsanto continues to lose more Roundup lawsuits.

 

Subscribe
Notify of
0 Comments
Inline Feedbacks
View all comments
You May Also Like

NUS appoints Board of Trustee member and lawyer as chair of review committee on sexual misconduct

In an email to students and staff of The National University of…

吴资政捍卫部长高薪引网民怒火 全球最高薪仍不足?

关于部长“高薪养廉”议题,早前就已引起人们非议。各大网络新闻近期报导,荣誉国务资政吴作栋在一则谈话音频中,批评居民建议部长减薪乃民粹主义做法,致使部长薪资争议在社交媒体空间重燃,问责我国部长表现,是否与他们的高薪相符? 有关对话是在本月2日,于职工总会中心举行的东南区研讨会上,吴作栋回答基层居民的提问。当时,70岁的布莱德岭居民委员会成员阿都阿兹说,年长者为了生存,即使入古稀之年也不能退休,还要继续工作,令他感到忧虑。他询问吴资政,为何不从国防开销和部长薪资中,提取一部分来改善年长者的生活? 吴资政部属提供完整对话逐字稿,本社在昨日翻译还原完整对谈内容。 吴作栋首先询问居民阿都阿兹,如果年长者不从事打扫清洁工作,还有谁愿意去做?如果请外劳又可能引发外劳泛滥问题,年长者也失去增加收入机会。他感谢阿都阿兹关心年长者情况,惟不认同削减国防开销,因为要捍卫小红点,需要有先进雷达来提前侦测来犯敌机,这些都要花钱。 “你说的对,得从哪里拿钱。如果你建议起消费税两巴仙,来支付年长者退休金,我必须大大表扬你。但你说的是,砍国防部预算,一巴仙也可以。此外,你要砍部长薪资。这是很民粹的,我告诉你,部长薪水还不够;再现实一点,你是否知道,现在公务员赚得都比部长多?再减薪会导致没有人愿意为政府效力。” 吴作栋也举例,现任律政暨卫生高级部长唐振辉,在当部长前的年收入超过两百万,为了服务人民毅然放弃高薪;如果有人在外头都没办法赚到百万收入,却要成为部长,他也不会聘请,因为这样只会招来非常庸俗之人。 有者对吴资政言论表示失望,也批评他在谈话中一味捍卫部长高薪和国防预算,但是对如何改善年长者低收入劳动的处境,着墨太少,没有提出具体建议。 网民江金顺(译音)在新加坡时事论坛脸书专页《议论政策论坛》留言感慨,过去第一代开国元勋,如吴庆瑞博士、杜进才博士、拉惹勒南、EW巴克等,都是任劳任怨为民服务,即使只有区区数千元却从没有嫌薪水太低。 “他们高尚的品格、正直廉明,还能够把小红点打造成“亚洲四小龙”之一。” 紧接着其他网民也加入论战: 网民KH NGAI:所谓“部长薪资不足”,早在李光耀仍任总理时就提出,但近十载我国部长薪资已是全球最高!但是人民行动党还是招揽许多“合格”专业医生、纸上将军、律师和会计师等,成为被党操控的扯线木偶部长和议员!很简单,谁会愿意去做较低薪资的工作?他们基本上就是贪婪!…

ST report on Bukit Brown "concessions" erroneous: SHS

The following is from the Singapore Heritage Society’s Facebook page: On 12…

Unemployment rate for S’poreans up from 3 to 3.3 per cent but Minister Josephine Teo says “not alarming”

Ministry of Manpower (MOM) released preliminary employment data today (30 Jan) showing…